INTRODUCTION

41
The process in which drugs are discovered and developed has fundamentally changed since the 42 inception of the pharmaceutical industry and continues to evolve. Several research groups have 43 peered into the past to identify trends in pharmaceutical innovation based upon FDA approved 44 medicines (1-3). The Center for Research Innovation in Biotechnology (CRIB) at Washington 3 50 once approved but no longer marketed as a result of toxicity, lack of efficacy, obsolescence, 51 production issues, or lack of demand.
53
A handful of reviews on the biopharmaceutical industry trends and innovation sources revealed a 54 trove of findings, many unexpected, and all supported by objective data (all of which we have made 55 public). As one example, a handful of organizations have recently come to control two-thirds of NMEs 56 and these marketing organizations often have little or no internal drug discovery or development 57 activities (4). Whereas large, traditional pharmaceutical companies receive most FDA approvals, 58 upstart biotechnology companies increasingly dominate early-stage discovery (including patents 59 and Investigational New Drug (IND) applications) (5). The NME database also revealed the causes 60 and impact of corporate consolidation in transforming research and development. Whereas 60% of 61 all acquired biotechnology companies were acquired within 5 years (before or after) their first NME 62 approval was granted, the number of new organizations to receive their first approval has not kept 63 pace (6). Consequently, the net number of research organizations that remain active and 64 independent in new drug research has has eroded from over 200 firms in 2004 to 100 firms at the 65 end of 2015 (7) .
67
Based on findings with FDA-approved medicines, we analyzed the mechanistic basis and therapeutic 68 indications of FDA approved medicines and changes over time. In some cases, these works 69 emphasized therapeutic areas (e.g., the decline in anti-infectives or the rise in oncology (8) databases to explore the current landscape of clinical stage pharmaceuticals and found a collection 120 of databases having drug records that display some evidence of clinical experience. (17), an encyclopedia of active pharmaceutical 130 ingredients, can be filtered to clinical compounds by selecting "Approved", "Withdrawn",
131
"Investigational", "Illicit", or "Nutraceutical" from their "Drug Group" metadata field. Other databases 132 focus explicitly on approved or withdrawn medicines, making their whole catalog of drugs relevant 133 in terms of clinical experience.
135
In a study that inspired the creation of CDEK, our group downloaded the clinical-stage active 136 pharmaceutical ingredients from the sources listed in 
212
Several open drug-compound databases containing clinically tested therapeutics to capture active 213 pharmaceutical ingredients with evidence of clinical testing outside of the ClinicalTrials.gov registry.
214
These databases included Drugbank (17), ChEMBL(16), PubChem(15), SuperDrug2 (19),
215
DrugCentral (20), WITHDRAWN(21), repoDB (22) and CRIB NME (4). The first three of these 216 databases were subsetted to access only those therapeutics with evidence of clinical testing, while 217 the remainder contain soley clinically-tested therapeutics (approved by a regulatory agency, 218 withdrawn from the market for any reason, or associated with a clinical trial). All DrugBank (v5.0.7) 219 compounds labeled "experimental" were excluded from CDEK as DrugBank defines "experimental" 220 as "drugs that are at the preclinical or animal testing stage." The ChEMBL database labels drug CDEK. We manually validated and collapsed these entries into 24,728 unique CDEK organizations.
252
Furthermore, AACT has 104,627 unique interventions names that we manually validated and 253 collapsed to 17,096 CDEK active pharmaceutical ingredients. During the curation process, we stored 254 all names, which had been collapsed into single organizations as "alternative names". This allows for 255 users to search many different terms in our web application.
256 257
CDEK Contents
258 Table 2 provides summary statistics of CDEK contents: active pharmaceutical ingredients (n = 259 22,292), clinical trials (n = 127,223), and organizations (n = 24,728). displays, a list of alternative names is given. For those interested in the source data, or who seek to 287 visualize the ingested reference, CDEK allows the user to link to external cross-referencing databases.
261
288
Users are directed to an advanced query functionality to access the granular CDEK data.
290
The advanced query functionality (cdek.wustl.edu/query/) provides users with more control over 291 the metadata are used to filter the dataset. A dynamically generated user-interface (UI) allows a user trend is almost two-thirds (64%) of the unique CDEK records were sponsored by for profit Figure 5 : Our advanced query builder allows users to filter down CDEK data to very granular details. In this example, the data returned will be all unique Phase III clinical trials studying lung or cardiovascular diseases, excluding vaccines, that were ran by GlaxoSmithKline as the lead sponsor between 2012 and 2017. Figure 6 : Heatmap displaying the overlap in active pharmaceutical ingredients (APIs) between any two databases in CDEK. The coloring and number displayed at the intersection between any two databases is the total number of shared APIs. The total number of unique APIs from each database that has evidence of clinical experience is noted in paranthesis next to each database name label.
